

Table S1. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in KHNMC cohort.

	Before PS adjustment			After PS adjustment		
	Pitavastatin (n=981)	Atorvastatin+ Rosuvastatin (n=5997)	Std. diff	Pitavastatin (n=945)	Atorvastatin+ Rosuvastatin (n=1745)	Std. diff
Age group						
20-24	<0.5	0.3	-0.04	<0.5	0.4	-0.06
25-29	<0.5	0.8	-0.05	<0.5	1.1	-0.07
30-34	1.2	1.4	-0.02	1.2	1.5	-0.03
35-39	4.3	3.2	0.06	4.1	4.4	-0.01
40-44	5.6	5.1	0.02	5.5	5.1	0.02
45-49	8.8	9.1	-0.01	8.9	9.9	-0.04
50-54	16.1	13.3	0.08	16.2	15.8	0.01
55-59	19.3	17.2	0.05	19.2	17.2	0.05
60-64	16.3	14.7	0.04	16.6	15.9	0.02
65-69	10.5	11.2	-0.02	10.4	11.3	-0.03
70-74	6.7	9.7	-0.11	6.7	7.1	-0.02
75-79	4.8	6.8	-0.08	4.9	5.0	0.00
80-84	4.0	4.5	-0.02	4.0	3.4	0.03
85-89	1.5	2.1	-0.04	1.6	1.4	0.01
90-94	<0.5	0.5	-0.06	<0.5	0.3	-0.02
Female	65.1	56.3	0.18	64.1	66.6	-0.05
Charlson comorbidity index*	0.38	0.58	-0.20	0.38	0.43	-0.04
Hyperlipidemia	43.2	37.0	0.13	42.4	45.9	-0.07
Hypertensive disorder	26.7	29.0	-0.05	27.1	26.0	0.02
Atrial fibrillation	0.9	1.8	-0.07	1.0	1.3	-0.03
Cerebrovascula r disease	5.2	7.9	-0.11	5.4	4.0	0.07
Heart disease	15.4	24.7	-0.23	16.0	14.1	0.05
Heart failure	15.4	24.7	-0.23	16.0	14.1	0.05
Ischemic heart disease	6.2	12.4	-0.21	6.6	5.4	0.05

Chronic liver disease	<0.5	0.1	0.05	<0.5	<0.3	0.06
Chronic obstructive lung disease	1.4	1.2	0.02	1.5	0.7	0.07
Renal impairment	1.1	2.8	-0.12	1.2	1.1	0.00
Gastroesophageal reflux disease	4.5	4.1	0.02	4.6	4.5	0.00
Osteoarthritis	1.8	1.7	0.01	1.9	1.5	0.03
Dementia	1.9	1.3	0.05	2.0	1.2	0.06
Depressive disorder	1.3	1.9	-0.05	1.3	1.9	-0.05
Visual system disorder	5.1	5.5	-0.01	5.3	5.1	0.01
Medication use						
RAS blocker	16.7	22.9	-0.15	16.9	15.3	0.04
Beta blocker	15.2	19.8	-0.12	14.9	14.6	0.01
Calcium channel blockers	11.4	18.4	-0.20	10.9	8.5	0.08
Diuretics	11.3	13.5	-0.07	11.1	10.0	0.04
Antibiotics	19.0	23.3	-0.11	18.7	16.8	0.05
NSAIDs	23.2	0.09	25.8	29.1	-0.07	23.2
Drugs for acid related disorders	55.7	58.0	-0.05	55.2	54.9	0.01
Drugs for obstructive airway diseases	5.7	5.9	-0.01	5.8	4.8	0.05
Immunosuppressants	3.7	1.5	0.14	3.5	3.8	-0.02

*Romano's Adaptation of the Charlson comorbidity index was used and presented as mean value. All other variables are presented as percent of the sample size.

PS, propensity score; RAS, renin-angiotensin system; NSAIDs, non-steroidal anti-inflammatory drugs

Table S2. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in WKUH cohort.

	Before PS adjustment			After PS adjustment		
	Pitavastatin (n=1393)	Atorvastatin+ Rosuvastatin (n=8642)	Std. diff	Pitavastatin (n=1155)	Atorvastatin+ Rosuvastatin (n=2019)	Std. diff
Age group						
20-24	0.5	0.2	0.05	0.4	0.5	-0.01
25-29	1.0	0.5	0.06	0.9	0.8	0.00
30-34	2.1	0.9	0.10	2.2	1.8	0.03
35-39	3.2	2.1	0.07	3.0	2.9	0.01
40-44	5.4	4.6	0.04	5.3	6.3	-0.04
45-49	8.6	7.5	0.04	7.9	8.5	-0.02
50-54	13.4	11.8	0.05	13.9	13.7	0.00
55-59	16.5	14.2	0.06	16.2	15.9	0.01
60-64	12.9	13.4	-0.02	12.6	12.3	0.01
65-69	11.6	13.3	-0.05	11.9	12.1	-0.01
70-74	10.7	12.3	-0.05	10.7	10.2	0.02
75-79	8.1	10.6	-0.09	8.7	8.4	0.01
80-84	4.0	5.8	-0.08	4.2	4.5	-0.01
85-89	1.6	2.3	-0.06	1.7	1.6	0.01
90-94	<0.4	0.4	-0.04	<0.4	0.3	-0.01
Female	52.8	49.6	0.06	51.7	52.1	-0.01
Charlson comorbidity index*	1.02	0.91	0.08	0.89	0.94	-0.03
Hyperlipidemia	32.2	31.4	0.02	32.3	32.5	0.00
Hypertensive disorder	39.0	43.5	-0.09	40.0	39.7	0.01
Atrial fibrillation	5.4	2.9	0.12	5.7	6.0	-0.01
Cerebrovascula r disease	5.5	11.3	-0.21	6.3	4.9	0.06
Peripheral vascular disease	3.9	0.9	0.20	1.6	1.9	-0.02
Heart failure	7.6	3.1	0.20	5.7	7.3	-0.06

Ischemic heart disease	7.7	19.7	-0.35	9.1	8.2	0.03
Chronic liver disease	0.7	0.5	0.03	0.8	0.3	0.06
Chronic obstructive lung disease	1.1	1.4	-0.02	1.0	1.4	-0.04
Renal impairment	7.6	2.1	0.26	6.5	8.3	-0.07
Gastroesophageal reflux disease	3.9	2.3	0.09	3.5	3.4	0.01
Osteoarthritis	2.1	1.8	0.03	2.0	1.8	0.01
Dementia	1.3	3.3	-0.14	1.3	1.7	-0.03
Depressive disorder	2.8	2.9	-0.01	2.3	2.6	-0.02
Visual system disorder	5.1	5.2	-0.01	4.8	4.9	0.00
Medication use						
RAS blocker	29.1	22.5	0.15	27.2	29.1	-0.04
Beta blocker	24.7	24.8	0.00	25.1	25.8	-0.02
Calcium channel blockers	20.1	24.7	-0.11	20.6	19.7	0.02
Diuretics	22.8	19.2	0.09	17.8	19.2	-0.04
Antibiotics use	24.3	26.1	-0.04	22.0	22.9	-0.02
NSAIDs use	23.0	22.7	0.01	18.7	20.6	-0.05
Drugs for acid related disorders	51.4	59.9	-0.17	49.7	49.0	0.01
Drugs for obstructive airway diseases	5.7	6.0	-0.01	5.5	5.2	0.01
Immunosuppressants	5.2	0.8	0.26	2.0	3.2	-0.08

*Romano's Adaptation of the Charlson comorbidity index was used and presented as mean value. All other variables are presented as percent of the sample size.

PS, propensity score; RAS, renin-angiotensin system; NSAIDs, non-steroidal anti-inflammatory drugs

Table S3. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in DCMC cohort.

	Before PS adjustment			After PS adjustment		
	Pitavastatin (n=1287)	Atorvastatin+ Rosuvastatin (n=7617)	Std. diff	Pitavastatin (n=1209)	Atorvastatin+ Rosuvastatin (n=2213)	Std. diff
Age group						
20-24	0.4	0.2	0.03	0.4	<0.2	0.05
25-29	<0.4	0.4	-0.02	<0.4	0.3	-0.01
30-34	0.7	0.8	-0.01	0.8	1.0	-0.02
35-39	2.3	1.8	0.04	2.1	2.0	0.01
40-44	4.2	3.3	0.05	4.0	3.6	0.02
45-49	7.3	6.7	0.03	7.3	6.7	0.02
50-54	11.5	12.5	-0.03	11.7	12.2	-0.02
55-59	15.0	15.5	-0.01	15.1	16.1	-0.03
60-64	15.0	15.0	0.00	15.5	14.9	0.01
65-69	16.4	13.4	0.08	16.4	17.6	-0.03
70-74	11.0	12.8	-0.05	10.9	10.7	0.01
75-79	9.1	10.3	-0.04	9.1	8.8	0.01
80-84	4.7	5.2	-0.03	4.5	3.8	0.04
85-89	1.5	1.7	-0.02	1.6	2.0	-0.03
90-94	<0.4	0.3	-0.02	<0.4	<0.2	0.04
Female	64.3	57.4	0.14	64.4	66.0	-0.04
Charlson comorbidity index*	1.05	1.00	0.04	1.03	1.05	-0.01
Hyperlipidemia	68.3	63.0	0.11	70.4	70.6	0.00
Hypertensive disorder	37.5	32.1	0.11	36.9	38.7	-0.04
Atrial fibrillation	6.3	3.9	0.11	5.6	6.9	-0.05
Cerebrovascula r disease	12.5	13.3	-0.02	12.7	13.7	-0.03
Peripheral vascular disease	16.5	12.0	0.13	15.3	17.3	-0.05
Heart failure	8.3	7.7	0.02	8.0	7.8	0.01

Ischemic heart disease	14.7	23.8	-0.23	14.5	12.9	0.05
Chronic liver disease	0.6	0.5	0.02	0.6	0.3	0.04
Chronic obstructive lung disease	1.9	1.8	0.01	1.7	1.6	0.00
Renal impairment	1.3	1.5	-0.01	1.3	1.6	-0.02
Gastroesophageal reflux disease	9.0	8.4	0.02	8.0	8.6	-0.02
Osteoarthritis	5.6	2.9	0.14	4.4	5.0	-0.03
Dementia	2.1	2.6	-0.03	2.1	2.2	-0.01
Depressive disorder	3.3	3.9	-0.03	3.2	4.1	-0.04
Visual system disorder	7.3	6.2	0.05	7.6	7.4	0.01
Medication use						
RAS blocker	16.6	11.7	0.14	15.5	16.1	-0.02
Beta blocker	30.0	32.2	-0.05	27.4	26.8	0.01
Calcium channel blockers	16.1	17.8	-0.05	16.1	16.2	0.00
Antibiotics use	13.6	14.9	-0.04	13.4	12.8	0.02
NSAIDs	28.2	24.7	0.08	28.1	29.2	-0.02
Drugs for acid related disorders	32.2	36.8	-0.10	31.3	31.9	-0.01
Drugs for obstructive airway diseases	5.9	4.3	0.07	5.5	5.3	0.01
Immunosuppressants	5.6	3.3	0.12	5.9	6.1	-0.01

*Romano's Adaptation of the Charlson comorbidity index was used and presented as mean value. All other variables are presented as percent of the sample size.

PS, propensity score; RAS, renin-angiotensin system; NSAIDs, non-steroidal anti-inflammatory drugs

Table S4. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in AUMC cohort.

	Before PS adjustment			After PS adjustment		
	Pitavastatin (n=2002)	Atorvastatin + Rosuvastatin (n=17930)	Std. diff	Pitavastatin (n=1985)	Atorvastatin + Rosuvastatin (n=3889)	Std. diff
Age group						
20-24	0.2	0.3	-0.01	0.3	0.4	-0.02
25-29	0.4	0.6	-0.02	0.5	0.7	-0.03
30-34	1.3	1.6	-0.02	1.3	1.7	-0.03
35-39	4.0	3.6	0.02	4.1	4.4	-0.01
40-44	6.8	7.0	-0.01	6.8	7.4	-0.02
45-49	12.5	11.7	0.03	12.6	12.5	0.00
50-54	18.3	16.2	0.06	18.4	17.1	0.04
55-59	18.1	15.4	0.07	17.8	17.2	0.01
60-64	13.5	13.5	0.00	13.4	14.0	-0.02
65-69	9.5	11.0	-0.05	9.5	9.4	0.00
70-74	7.4	8.8	-0.05	7.3	7.6	-0.01
75-79	5.2	6.2	-0.04	5.2	4.6	0.03
80-84	1.9	3.0	-0.07	1.9	2.0	0.00
85-89	0.7	0.9	-0.02	0.7	0.7	0.00
90-94	<0.2	0.2	-0.03	<0.3	0.2	-0.02
Female	52.8	50.5	0.05	52.5	53.4	-0.02
Charlson comorbidity index*	0.68	0.77	-0.06	0.66	0.69	-0.02
Hyperlipidemia	17.4	15.2	0.06	17.7	17.5	0.00
Hypertensive disorder	24.6	30.1	-0.12	24.5	23.7	0.02
Atrial fibrillation	1.4	1.7	-0.02	1.5	1.4	0.01
Cerebrovascular disease	4.6	3.6	0.05	4.6	4.7	0.00
Peripheral vascular disease	<0.2	0.3	-0.03	<0.3	0.4	-0.04

Heart failure	0.8	1.3	-0.05	0.9	0.9	-0.01
Ischemic heart disease	7.9	15.3	-0.23	7.9	6.7	0.05
Chronic liver disease	0.6	0.4	0.04	0.7	0.7	-0.01
Chronic obstructive lung disease	1.1	1.1	0.00	1.2	0.9	0.03
Renal impairment	0.6	2.0	-0.12	0.7	0.8	-0.02
Gastroesophageal reflux disease	4.6	4.6	0.00	4.7	4.8	-0.01
Osteoarthritis	1.5	2.2	-0.05	1.5	2.0	-0.04
Dementia	0.7	1.0	-0.03	0.8	0.9	-0.02
Depressive disorder	1.4	1.5	0.00	1.5	1.6	-0.01
Visual system disorder	4.3	3.8	0.03	4.2	4.7	-0.02
Medication use						
Beta blocker	17.6	19.8	-0.05	17.6	18.1	-0.01
Calcium channel blockers	15.7	19.6	-0.10	15.7	14.4	0.04
Diuretics	11.7	13.5	-0.05	11.7	10.9	0.03
Antibiotics use	17.6	22.1	-0.11	17.0	16.2	0.02
NSAIDs use	22.4	23.6	-0.03	21.9	21.4	0.01
Drugs for acid related disorders	40.2	43.7	-0.07	39.8	38.7	0.02
Drugs for obstructive airway diseases	4.1	6.1	-0.09	4.1	3.9	0.01
Immunosuppressants	4.1	2.3	0.10	3.8	4.4	-0.03

*Romano's Adaptation of the Charlson comorbidity index was used and presented as mean value. All other variables are presented as percent of the sample size.

PS, propensity score; RAS, renin-angiotensin system; NSAIDs, non-steroidal anti-inflammatory drugs

Table S5. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in PNUH cohort.

	Before PS adjustment			After PS adjustment		
	Pitavastatin (n=649)	Atorvastatin+ Rosuvastatin (n=3847)	Std. diff	Pitavastatin (n=585)	Atorvastatin+ Rosuvastatin (n=1048)	Std. diff
Age group						
20-24	<0.8	0.7	-0.03	<0.9	0.6	-0.04
25-29	1.1	0.9	0.02	<0.9	0.8	-0.01
35-39	3.8	2.6	0.07	3.8	4.1	-0.02
40-44	5.0	3.5	0.07	4.6	4.0	0.03
45-49	7.6	5.1	0.10	6.8	6.3	0.02
50-54	12.2	10.3	0.06	12.0	12.4	-0.01
55-59	18.0	15.5	0.07	17.8	19.1	-0.03
60-64	18.1	17.1	0.03	19.0	17.7	0.03
65-69	12.7	14.1	-0.04	12.5	13.2	-0.02
70-74	8.7	12.7	-0.13	9.2	8.1	0.04
75-79	7.5	10.2	-0.10	8.0	7.7	0.01
80-84	2.4	4.3	-0.10	2.6	3.1	-0.03
85-89	<0.8	1.2	-0.07	<0.9	0.9	-0.02
Female	57.8	56.4	0.03	57.9	58.5	-0.01
Charlson comorbidity index*	1.45	1.36	0.04	1.35	1.38	-0.01
Hyperlipidemia	11.0	31.4	-0.52	11.3	9.9	0.04
Hypertensive disorder	16.8	27.3	-0.26	16.6	14.8	0.05
Atrial fibrillation	2.0	3.0	-0.06	2.1	0.7	0.12
Cerebrovascula r disease	6.1	9.1	-0.11	6.7	5.6	0.04
Peripheral vascular disease	<0.8	0.4	-0.01	<0.9	<0.5	0.02
Heart failure	1.8	3.8	-0.12	1.9	1.3	0.05
Ischemic heart disease	3.4	11.2	-0.31	3.8	2.8	0.05
Chronic liver	<0.8	1.2	-0.06	<0.9	1.4	-0.07

disease						
Chronic obstructive lung disease	3.0	4.9	-0.10	3.2	2.6	0.04
Renal impairment	2.0	5.3	-0.18	1.9	2.0	-0.01
Gastroesophageal reflux disease	4.3	4.8	-0.03	4.8	4.0	0.04
Osteoarthritis	<0.8	1.5	-0.10	<0.9	1.2	-0.07
Dementia	0.8	1.3	-0.06	0.9	1.0	-0.02
Depressive disorder	2.0	3.3	-0.08	2.2	1.8	0.03
Visual system disorder	6.7	7.1	-0.02	6.7	6.2	0.02
Medication use						
RAS blocker	12.3	18.3	-0.17	12.6	12.1	0.02
Beta blocker	12.5	21.4	-0.24	13.5	11.5	0.06
Calcium channel blockers	8.7	12.4	-0.12	8.7	6.5	0.08
Diuretics	9.6	14.8	-0.16	9.7	8.2	0.05
Antibiotics use	17.2	23.6	-0.16	16.2	14.4	0.05
NSAIDs use	17.5	16.5	0.03	16.2	15.6	0.02
Drugs for acid related disorders	28.5	33.6	-0.11	27.7	25.6	0.05
Drugs for obstructive airway diseases	6.6	7.7	-0.04	6.7	4.9	0.08
Immunosuppressants	5.6	2.1	0.18	4.1	3.8	0.01

*Romano's Adaptation of the Charlson comorbidity index was used and presented as mean value. All other variables are presented as percent of the sample size.

PS, propensity score; RAS, renin-angiotensin system; NSAIDs, non-steroidal anti-inflammatory drugs

Table S6. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in EUMC cohort.

	Before PS adjustment			After PS adjustment		
	Pitavastatin (n=1159)	Atorvastatin+ Rosuvastatin (n=4570)	Std. diff	Pitavastatin (n=1139)	Atorvastatin+ Rosuvastatin (n=2018)	Std. diff
Age group						
20-24	0.7	0.5	0.02	0.7	0.5	0.02
25-29	<0.4	1.1	-0.12	<0.4	0.4	-0.05
30-34	2.0	2.2	-0.01	1.9	2.5	-0.04
35-39	4.1	3.7	0.02	4.0	4.5	-0.03
40-44	7.5	6.3	0.04	7.5	7.3	0.01
45-49	11.4	10.8	0.02	11.5	12.3	-0.03
50-54	17.7	14.7	0.08	17.7	17.1	0.02
55-59	15.6	15.2	0.01	15.6	15.2	0.01
60-64	13.8	12.8	0.03	13.8	13.1	0.02
65-69	9.8	11.1	-0.04	9.8	9.6	0.01
70-74	9.0	8.8	0.01	9.0	8.3	0.03
75-79	4.9	6.5	-0.07	4.8	4.6	0.01
80-84	2.3	3.8	-0.09	2.3	2.6	-0.02
85-89	0.9	1.9	-0.09	0.9	1.5	-0.06
90-94	<0.4	0.4	-0.04	<0.4	<0.2	0.01
Female	56.0	58.9	-0.06	56.1	54.8	0.03
Charlson comorbidity index*	0.59	0.77	-0.17	0.58	0.61	-0.02
Hyperlipidemi a	37.8	33.1	0.10	38.1	41.4	-0.07
Hypertensive disorder	30.4	24.1	0.14	30.3	32.8	-0.06
Atrial fibrillation	0.7	0.5	0.02	0.6	0.6	0.01
Cerebrovascul ar disease	6.0	7.6	-0.06	6.0	5.7	0.01
Peripheral vascular disease	3.3	3.7	-0.02	3.2	3.2	0.00

Heart failure	0.7	1.3	-0.06	0.6	1.5	-0.09
Ischemic heart disease	11.1	8.4	0.09	11.0	12.3	-0.04
Chronic obstructive lung disease	0.5	0.9	-0.04	0.5	0.6	-0.01
Renal impairment	2.0	1.8	0.02	2.1	1.6	0.04
Gastroesophageal reflux disease	3.1	3.4	-0.02	3.2	3.3	0.00
Dementia	1.0	3.4	-0.16	1.1	1.2	-0.01
Depressive disorder	2.6	2.3	0.02	2.6	1.9	0.05
Visual system disorder	5.0	4.6	0.02	5.0	4.0	0.05
Medication use						
RAS blocker	32.7	28.0	0.10	31.9	35.0	-0.07
Beta blocker	13.9	14.9	-0.03	14.1	14.9	-0.02
Calcium channel blockers	21.9	21.9	0.00	21.8	22.4	-0.01
Diuretics	15.9	13.3	0.07	15.8	17.3	-0.04
Antibiotics use	18.9	22.7	-0.09	18.7	18.0	0.02
NSAIDs use	18.0	23.5	-0.14	17.9	17.5	0.01
Drugs for acid related disorders	30.6	35.8	-0.11	30.4	28.1	0.05
Immunosuppressants	3.0	2.8	0.01	3.1	2.9	0.01

*Romano's Adaptation of the Charlson comorbidity index was used and presented as mean value. All other variables are presented as percent of the sample size.

PS, propensity score; RAS, renin-angiotensin system; NSAIDs, non-steroidal anti-inflammatory drugs

Table S7. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in NHIMC cohort.

	Before PS adjustment			After PS adjustment		
	Pitavastatin (n=986)	Atorvastatin+ Rosuvastatin (n=10817)	Std. diff	Pitavastatin (n=865)	Atorvastatin+ Rosuvastatin (n=1637)	Std. diff
Age group						
20-24	<0.5	0.3	0.03	<0.6	0.5	-0.02
25-29	<0.5	0.4	0.00	<0.6	0.7	-0.05
30-34	1.0	0.7	0.03	1.1	0.5	0.07
35-39	1.8	2.4	-0.04	1.9	2.4	-0.03
40-44	4.1	5.6	-0.07	4.0	3.4	0.03
45-49	9.4	8.2	0.04	9.9	9.1	0.02
50-54	14.3	12.2	0.06	14.5	15.4	-0.03
55-59	15.3	13.0	0.07	15.2	13.8	0.04
60-64	14.7	12.1	0.08	14.8	14.7	0.00
65-69	11.4	13.1	-0.05	10.8	11.1	-0.01
70-74	11.7	12.7	-0.03	11.3	10.1	0.04
75-79	8.7	10.1	-0.05	8.9	9.1	-0.01
80-84	4.3	6.0	-0.07	4.5	5.9	-0.06
85-89	2.0	2.7	-0.04	2.0	2.8	-0.05
90-94	<0.5	0.6	-0.06	<0.6	<0.3	0.03
Female	63.8	57.5	0.13	63.3	64.0	-0.01
Charlson comorbidity index*	0.82	0.78	0.03	0.77	0.77	0.00
Hyperlipidemia	19.4	19.1	0.01	21.9	21.8	0.00
Hypertensive disorder	38.7	34.8	0.08	34.6	37.1	-0.05
Atrial fibrillation	1.2	1.7	-0.04	1.4	1.2	0.02
Cerebrovascula r disease	6.0	9.4	-0.13	6.8	5.8	0.04
Peripheral vascular disease	6.2	6.0	0.01	5.6	6.4	-0.03
Heart failure	0.6	1.6	-0.10	0.7	1.1	-0.04

Ischemic heart disease	5.7	9.9	-0.16	6.4	6.7	-0.01
Chronic liver disease	<0.5	0.4	-0.07	<0.6	<0.3	-0.01
Chronic obstructive lung disease	1.2	1.4	-0.01	1.2	0.9	0.03
Renal impairment	10.1	3.3	0.27	6.5	8.0	-0.06
Gastroesophageal reflux disease	3.6	2.9	0.04	3.7	2.9	0.05
Osteoarthritis	1.0	1.9	-0.07	1.1	1.5	-0.04
Dementia	2.7	3.7	-0.06	3.2	3.7	-0.03
Depressive disorder	4.0	4.4	-0.02	4.5	3.7	0.04
Visual system disorder	6.2	5.5	0.03	6.5	6.1	0.02
Medication use						
RAS blocker	35.6	29.0	0.14	29.8	34.0	-0.09
Beta blocker	17.8	19.6	-0.05	18.8	20.3	-0.04
Calcium channel blockers	30.4	29.4	0.02	29.2	29.6	-0.01
Diuretics	12.6	15.9	-0.09	13.2	14.9	-0.05
Antibiotics use	15.4	19.6	-0.11	14.7	14.0	0.02
NSAIDs use	19.0	25.8	-0.16	19.7	16.9	0.07
Drugs for acid related disorders	25.0	32.4	-0.16	25.4	23.1	0.05
Drugs for obstructive airway diseases	4.1	6.0	-0.09	3.9	4.0	0.00
Immunosuppressants	0.8	0.8	0.00	0.7	0.8	-0.01

*Romano's Adaptation of the Charlson comorbidity index was used and presented as mean value. All other variables are presented as percent of the sample size.

PS, propensity score; RAS, renin-angiotensin system; NSAIDs, non-steroidal anti-inflammatory drugs

Table S8. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in MJH cohort.

	Before PS adjustment			After PS adjustment		
	Pitavastatin (n=765)	Atorvastatin+ Rosuvastatin (n=2953)	Std. diff	Pitavastatin (n=695)	Atorvastatin+ Rosuvastatin (n=1173)	Std. diff
Age group						
20-24	<0.6	0.2	0.02	<0.7	<0.4	0.05
25-29	<0.6	0.5	-0.01	<0.7	0.6	-0.02
30-34	1.0	1.1	-0.01	1.2	0.7	0.04
35-39	2.6	3.3	-0.04	2.6	4.4	-0.10
40-44	5.8	5.8	0.00	6.0	6.5	-0.02
45-49	9.7	9.6	0.00	9.6	10.0	-0.01
50-54	15.7	13.6	0.06	15.7	14.1	0.04
55-59	12.6	14.5	-0.06	12.5	14.6	-0.06
60-64	15.5	14.3	0.03	15.7	14.8	0.02
65-69	12.1	10.3	0.06	11.8	10.2	0.05
70-74	9.9	9.7	0.01	9.5	8.3	0.04
75-79	8.1	8.7	-0.02	8.5	7.9	0.02
80-84	4.1	5.3	-0.06	4.5	4.6	-0.01
85-89	1.4	2.3	-0.06	1.0	2.2	-0.10
90-94	<0.6	0.6	-0.01	<0.7	0.8	-0.05
Female	62.5	51.7	0.22	60.6	60.8	0.00
Charlson comorbidity index*	0.69	0.70	-0.01	0.65	0.66	-0.01
Hyperlipidemia	71.3	60.0	0.24	68.5	69.0	-0.01
Hypertensive disorder	37.2	40.9	-0.07	37.7	40.4	-0.06
Atrial fibrillation	1.2	1.9	-0.06	1.3	0.9	0.03
Cerebrovascula r disease	6.7	8.5	-0.07	6.9	7.7	-0.03
Peripheral vascular disease	1.5	0.9	0.06	1.4	1.2	0.03
Heart failure	6.4	7.2	-0.03	6.3	5.3	0.05

Ischemic heart disease	7.7	18.6	-0.33	8.3	6.1	0.09
Chronic liver disease	<0.6	0.5	-0.04	<0.7	0.4	-0.02
Chronic obstructive lung disease	<0.6	1.0	-0.10	<0.7	1.1	-0.10
Renal impairment	3.0	1.3	0.12	2.7	1.4	0.10
Gastroesophageal reflux disease	11.9	18.4	-0.18	12.2	12.7	-0.01
Osteoarthritis	3.0	3.0	0.00	3.0	2.8	0.01
Dementia	3.6	4.9	-0.06	3.9	5.0	-0.05
Depressive disorder	6.2	6.0	0.01	5.6	5.9	-0.01
Schizophrenia	1.2	0.4	0.08	1.3	0.4	0.09
Visual system disorder	5.2	6.4	-0.05	5.0	7.0	-0.08
Medication use						
RAS blocker	25.8	27.2	-0.03	26.2	26.8	-0.01
Beta blocker	23.8	24.2	-0.01	24.0	21.4	0.06
Calcium channel blockers	9.0	10.6	-0.05	9.8	7.7	0.07
Diuretics	15.2	14.9	0.01	15.7	15.8	0.00
Antibiotics use	23.6	27.8	-0.10	24.5	22.2	0.05
NSAIDs	24.2	28.1	-0.09	25.2	25.0	0.00
Drugs for acid related disorders	40.2	47.9	-0.16	40.4	37.9	0.05
Drugs for obstructive airway diseases	4.8	4.4	0.02	4.7	4.0	0.04
Immunosuppressants	0.6	0.9	-0.03	0.7	1.6	-0.08

*Romano's Adaptation of the Charlson comorbidity index was used and presented as mean value. All other variables are presented as percent of the sample size.

PS, propensity score; RAS, renin-angiotensin system; NSAIDs, non-steroidal anti-inflammatory drugs

Table S9. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in KWMC cohort.

	Before PS adjustment			After PS adjustment		
	Pitavastatin (n=522)	Atorvastatin+ Rosuvastatin (n=8178)	Std. diff	Pitavastatin (n=506)	Atorvastatin+ Rosuvastatin (n=987)	Std. diff
Age group						
25-29	<0.9	0.5	-0.01	<1.0	<0.5	0.02
30-34	<0.9	0.9	-0.02	<1.0	1.0	-0.02
35-39	1.1	1.7	-0.04	1.2	2.1	-0.07
40-44	3.2	3.6	-0.02	3.4	3.9	-0.03
45-49	5.8	5.4	0.02	5.9	6.3	-0.02
50-54	10.0	9.7	0.01	10.1	9.1	0.03
55-59	14.1	12.3	0.06	14.8	13.1	0.05
60-64	12.8	13.2	-0.01	13.4	14.3	-0.03
65-69	13.9	12.4	0.04	13.6	12.6	0.03
70-74	14.3	13.7	0.02	13.8	12.2	0.05
75-79	11.7	12.5	-0.03	11.3	13.0	-0.05
80-84	7.5	8.8	-0.05	6.9	7.8	-0.03
90-94	0.9	1.3	-0.03	1.0	1.3	-0.03
Female	57.8	51.9	0.12	57.9	57.0	0.02
Charlson comorbidity index*	0.64	0.76	-0.11	0.65	0.68	-0.03
Hyperlipidemia	42.7	40.8	0.04	44.3	43.0	0.03
Hypertensive disorder	27.9	22.3	0.13	28.1	32.0	-0.09
Atrial fibrillation	5.8	3.7	0.10	5.9	6.1	-0.01
Cerebrovascul ar disease	6.0	11.7	-0.20	6.1	5.6	0.02
Peripheral vascular disease	1.3	1.1	0.02	1.4	0.7	0.07
Heart failure	3.4	4.0	-0.03	3.6	4.9	-0.07
Ischemic heart disease	16.0	16.3	-0.01	15.0	17.1	-0.06

Chronic liver disease	<0.9	0.3	0.06	<1.0	<0.5	0.04
Chronic obstructive lung disease	2.3	2.1	0.01	2.4	1.8	0.04
Renal impairment	0.9	1.8	-0.08	1.0	1.5	-0.04
Gastroesophageal reflux disease	4.0	3.6	0.02	3.8	5.3	-0.08
Osteoarthritis	2.3	2.1	0.01	2.4	2.5	-0.01
Dementia	1.9	2.7	-0.06	2.0	2.7	-0.05
Depressive disorder	4.3	3.5	0.04	4.0	3.8	0.01
Visual system disorder	6.6	8.1	-0.06	6.3	7.7	-0.05
Medication use						
RAS blocker	35.4	26.4	0.20	34.0	37.2	-0.07
Beta blocker	20.9	21.2	-0.01	21.1	22.6	-0.04
Calcium channel blockers	10.2	9.1	0.04	10.3	11.4	-0.04
Diuretics	21.7	14.8	0.18	19.8	23.1	-0.08
Antibiotics use	23.9	23.4	0.01	23.5	25.4	-0.04
NSAIDs	20.2	19.1	0.03	20.2	20.0	0.00
Drugs for acid related disorders	42.0	43.7	-0.03	42.1	41.1	0.02
Drugs for obstructive airway diseases	5.1	4.9	0.01	5.1	3.7	0.07
Immunosuppressants	<0.9	0.5	0.01	<1.0	0.7	-0.04

*Romano's Adaptation of the Charlson comorbidity index was used and presented as mean value. All other variables are presented as percent of the sample size.

PS, propensity score; RAS, renin-angiotensin system; NSAIDs, non-steroidal anti-inflammatory drugs